Dr Reddy’s Laboratories Share Price in Focus as Board Sets July 22 for Q1 FY27 Results

Dr Reddy’s Rs 1,344.40 (-0.94%). Q1 FY27 board meeting July 22, 2026. Trading window closed June 24 to July 24. Nomura Buy, target Rs 1,740. This is a key data point for anyone tracking the Dr Reddy’s Laboratories share price today.

Dr Reddy’s Laboratories share price slipped 0.94 percent to Rs 1,344.40 on Wednesday as the pharmaceutical major’s trading window remains closed ahead of its Q1 FY27 results, which the board has scheduled for July 22, 2026. The stock touched an intraday low of Rs 1,339.70 during the session.

The upcoming results will cover the quarter ended June 30, 2026, and come at a time when brokerages remain broadly constructive on the Dr Reddy’s Laboratories share price, with Nomura recently upgrading its target on the back of the company’s strategic shift toward branded generics and its consumer business.

Click Here – Get Free Investment Predictions

Dr Reddy’s Laboratories Q1 FY27 Results Date and Trading Window

Dr Reddy’s Laboratories has scheduled a board meeting for July 22, 2026 to consider the company’s unaudited standalone and consolidated financial results for the quarter ending June 30, 2026. In line with SEBI insider trading regulations, the trading window for dealing in the company’s securities has been closed from June 24, 2026 and will remain shut until 24 hours after the results are announced on July 22. Investors watching the Dr Reddy’s Laboratories share price should note this development closely.

The Q1 FY27 print follows a Q4 and full year FY26 result in which the company’s performance was impacted by a shelf stock adjustment related to lenalidomide of Rs 453 crore, along with impairment charges on CAR-T assets and provisions related to VAT liability, which together weighed on revenue growth, gross margin and EBITDA margin for the year. This detail is central to the near term outlook on the Dr Reddy’s Laboratories share price.

Brokerage View on Dr Reddy’s Laboratories Share Price

Nomura has upgraded its target price on Dr Reddy’s Laboratories to Rs 1,740 while reiterating a Buy rating, citing the company’s strategic shift toward branded generics and consumer health as a driver of sustained earnings growth and a potential valuation re-rating over time. This is a fresh input into the Dr Reddy’s Laboratories share price debate heading into results. This is likely to remain a talking point for the Dr Reddy’s Laboratories share price in coming sessions.

Check the Univest Screener for Live Pharma Sector Data

Quick take: the Dr Reddy’s Laboratories share price will likely stay range bound until fresh Q1 FY27 data lands on July 22.

Patent expirations between 2026 and 2030 are seen as offering a 3 to 5 billion dollar opportunity for Indian pharmaceutical companies in generics and biosimilars, and analysts note that firms including Dr Reddy’s, Lupin and Sun Pharma will need to manage the complexities of biologics manufacturing to capture meaningful market share from this wave. This factor will continue to influence the Dr Reddy’s Laboratories share price over the next few quarters.

Key Corporate Actions Around Dr Reddy’s Laboratories Share Price

Separately, Dr Reddy’s board approved a final dividend of Rs 8 per equity share for FY26 at its May results meeting, with the record date fixed for July 10, 2026, ahead of the company’s 42nd Annual General Meeting scheduled for July 23, 2026. The company also re-appointed Dr K P Krishnan as an Independent Director for a fresh five year term beginning January 2027. This is worth watching closely for anyone following the Dr Reddy’s Laboratories share price.

These are the factors most likely to matter for the Dr Reddy’s Laboratories share price in the days around the results.

Download the Univest iOS App or Univest Android App to track Dr Reddy’s Laboratories’ live price and results updates.

Conclusion

Dr Reddy’s Laboratories share price is likely to stay range bound in the near term with its trading window closed ahead of the July 22 Q1 FY27 results, even as brokerages including Nomura remain constructive on the stock’s medium term prospects following the company’s pivot toward branded generics and consumer health. Investors should treat the upcoming results, alongside the dividend record date and AGM, as the key near term catalysts for the stock. This article is for educational purposes and is not investment advice; consult a SEBI-registered investment adviser before making any investment decision.

FAQs on Dr Reddy’s Laboratories Share Price

1. When will Dr Reddy’s Laboratories announce Q1 FY27 results?

Ans. Dr Reddy’s Laboratories board will meet on July 22, 2026 to consider unaudited standalone and consolidated results for the quarter ended June 30, 2026.

2. Why is Dr Reddy’s Laboratories trading window closed?

Ans. In compliance with SEBI insider trading regulations, the trading window has been closed from June 24, 2026 and will reopen 24 hours after the Q1 FY27 results are announced on July 22.

3. What is Nomura’s target price on Dr Reddy’s Laboratories?

Ans. Nomura has a Buy rating on Dr Reddy’s Laboratories with a target price of Rs 1,740, citing the company’s strategic shift toward branded generics and consumer health.

4. What impacted Dr Reddy’s Laboratories Q4 FY26 results?

Ans. Q4 FY26 results were impacted by a shelf stock adjustment related to lenalidomide of about Rs 453 crore, along with impairment charges and VAT liability provisions, which weighed on revenue and margin growth.

5. What dividend did Dr Reddy’s Laboratories declare for FY26?

Ans. Dr Reddy’s Laboratories declared a final dividend of Rs 8 per equity share for FY26, with the record date set for July 10, 2026.

6. When is Dr Reddy’s Laboratories’ Annual General Meeting?

Ans. Dr Reddy’s Laboratories’ 42nd Annual General Meeting is scheduled for July 23, 2026, a day after the Q1 FY27 results are announced.